Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LNPEP | Q9UIQ6 | 8/20 | 0.54 |
| ▸ | ERAP2 | Q6P179 | 5/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 10/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 9/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.52 |
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | HPGD | P15428 | 5/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | BRD4 | O60885 | 1/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.44 |
| ▸ | MAPT | P10636 | 2/20 | 0.43 |
| ▸ | GLA | P06280 | 2/20 | 0.43 |
| ▸ | GAA | P10253 | 2/20 | 0.43 |
| ▸ | ATM | Q13315 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1637148 | 0.86 | LNPEP (0.43) | LNPEPERAP2KDM4EALDH1A1KMT2A | |
| SCHEMBL12214968 | 0.83 | CA1 (0.51) | LNPEPERAP2ALDH1A1KMT2ABRD4 | |
| SCHEMBL8260490 | 0.83 | CA1 (0.51) | LNPEPERAP2ALDH1A1KMT2ABRD4 | |
| SCHEMBL1638139 | 0.77 | MDM2 (0.44) | KDM4EALDH1A1KMT2ALMNAHPGD | |
| SCHEMBL2928021 | 0.75 | MEN1 (0.53) | ALDH1A1KMT2ALMNAMAPTGAA | |
| SCHEMBL7399477 | 0.74 | KDM4E (0.63) | KDM4EALDH1A1KMT2ALMNAHPGD | |
| SCHEMBL1979615 | 0.73 | BRD4 (0.49) | LNPEPERAP2KDM4EALDH1A1HPGD | |
| SCHEMBL15898542 | 0.73 | KDM4E (0.78) | LNPEPERAP2KDM4EALDH1A1KMT2A | |
| SCHEMBL12954612 | 0.72 | MEN1 (0.62) | KMT2AGAA | |
| SCHEMBL1206765 | 0.72 | HDAC3 (0.53) | LNPEPERAP2KDM4EALDH1A1HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110172212-A1 | AMINE-BASED COMPOUND AND USE THEREOF | KUREHA CORPORATION (JP) | 2011-07-14 | — | — | US | disclosed |
| US-7932281-B2 | Amine-based compound and use thereof | KUREHA CORPORATION (JP) | 2011-04-26 | — | — | US | disclosed |
| US-20070208007-A1 | Amine-Based Compound and Use Thereof | KUREHA CORPORATION (JP) | 2007-09-06 | — | — | US | disclosed |
| EP-1724263-A1 | BASIC AMINE COMPOUND AND USE THEREOF | Kureha Corporation (JP) | 2006-11-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110172212-A1 | AMINE-BASED COMPOUND AND USE THEREOF | NR0B2, NR5A2, NR1D2 | LNPEP 4384/4885ERAP2 3676/4885KDM4E 2406/4885 |
| US-20070208007-A1 | Amine-Based Compound and Use Thereof | NR0B2, NR5A2, NR2E1 | LNPEP 4503/4885ERAP2 3789/4885KDM4E 2871/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.